Form 4: Fortress Biotech Increases Stake in Avenue Therapeutics Following Warrant Exercise

Fortress Biotech, a 10% owner of Avenue Therapeutics, acquired 33,724 shares of common stock on March 31, 2025, as an equity fee related to a financing event.

Summary

• Fortress Biotech, Inc., a reporting person, increased its holdings in Avenue Therapeutics, Inc.
• On March 31, 2025, Fortress Biotech acquired 33,724 shares of Avenue Therapeutics' common stock.
• This acquisition was due to an equity fee granted to Fortress Biotech, representing 2.5% of the gross amount of any debt or equity financing consummated by Avenue Therapeutics.
• The shares were granted following the receipt of proceeds by Avenue Therapeutics from the exercise of previously issued warrants.
• Following the transaction, Fortress Biotech beneficially owns 328,524 shares of Avenue Therapeutics' common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to an equity fee agreement. The increase in ownership could be viewed slightly positively, but it's not a major event.

Positives

• Fortress Biotech increasing its stake in Avenue Therapeutics could be seen as a positive signal.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders and major shareholders. This filing indicates Fortress Biotech's increased investment in Avenue Therapeutics.

Stakeholder Impact

• The increased stake of Fortress Biotech in Avenue Therapeutics may reassure shareholders.

Key Dates

Keywords

Fortress Biotech, Avenue Therapeutics, Beneficial Ownership, Equity Fee, Warrant Exercise, ATXI, Common Stock